# Top 10 comparator extracts from lijecnicki vjesnik-139-365_cleaned.json

=== Ranked Comparator 1 (Extract #3, Placebo) — Score: 3 ===
re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. ta

=== Ranked Comparator 2 (Extract #1, Placebo) — Score: 2 ===
of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall
versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J
14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-

=== Ranked Comparator 3 (Extract #2, Placebo) — Score: 2 ===
umab for non-small-cell lung cancer. N Engl J Med 2006;355:
15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of
36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus
sequential chemoradiotherapy compared with concurrent chemoradio-
gemcitabine with either placebo or bevacizumab as fi rst-line therapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. S

